Is Eiko Lifescience overvalued or undervalued?

As of 23 June 2025, Eiko Lifescience's valuation grade has moved from fair to attractive, indicating a shift in perception regarding its value. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 45.06, an EV to EBITDA of 33.36, and a PEG ratio of 0.67, which suggests that the stock may be priced attractively relative to its growth potential.
In comparison to its peers, Eiko Lifescience's PE ratio is significantly higher than Life Insurance's 12.3 and Bajaj Finance's 34.19, but its PEG ratio of 0.67 is more favorable than Bajaj Finance's 2.33, indicating better growth prospects relative to its valuation. Despite recent underperformance against the Sensex, with a year-to-date return of -22.41% compared to the Sensex's 4.81%, the attractive valuation suggests that there may be potential for recovery and growth moving forward.